Peanut Allergy Pipeline | 15+ Companies & 15+ Medicines | DelveInsight

DelveInsight’s “Peanut Allergy Pipeline Insight, 2022” report provides comprehensive insights on more than 15 companies and more than 15 pipeline drugs across the Peanut Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers therapeutic assessment by product type, stage, route of administration and molecule type. It further highlights the inactive pipeline products in this space.

Recent Development Activities in the Peanut Allergy Pipeline

  • DBV is developing the Viaskin technology platform, which delivers biologically active compounds, including allergens, through intact skin. Viaskin is an electrostatic patch, based on Epicutaneous Immunotherapy, or EPIT®, that delivers an allergen directly to the superficial layers of the skin to activate the immune system by specifically targeting antigen-presenting cells without releasing the antigen into the bloodstream. It is currently in the pre-registration phase of development.
  • Dupilumab is an IL-4R antibody being developed by Regeneron Pharmaceuticals in collaboration with Sanofi for the treatment of peanut allergy. It is currently in the phase II development phase.
  • CNP-201 is a biodegradable nanoparticle that encapsulates peanut protein. It has the potential to treat peanut allergy sufferers by reducing the need for strict peanut avoidance and reducing the potentially deadly health risks associated with peanut allergy. It is currently in phase I/II development stage.

Highlights from the Peanut Allergy Pipeline Report

  • DelveInsight’s Peanut Allergy Pipeline analysis shows a robust space with more than 15 active players working to develop more than 15 pipeline therapies for the treatment of peanut allergy.
  • The leading peanut allergy companies work, such as DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma SL, Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy , Prota Therapeutics, IgGenix and others.
  • Promising Peanut Allergy Pipeline Therapies such as pnt ASIT+, VLP Peanut, HAL-MPE1, INT301, INP20, CNP-201, VE416, Dupilumab, Acalabrutinib, CA002, Omalizumab and others
  • The Peanut Allergy Companies and academics are working to assess challenges and look for opportunities that could impact Peanut Allergy’s R&D. The therapies under development are aimed at new approaches to treat/improve peanut allergy.

Request a sample and discover recent breakthroughs in the Peanut Allergy pipeline landscape @ Peanut Allergy Pipeline Outlook

Peanut allergy overview

A peanut allergy is a reaction that occurs when your body mistakenly identifies peanuts as harmful substances. When you eat peanuts or foods containing peanuts, your immune system — the body’s natural defense system that fights infection and disease — overreacts and can cause a serious, even life-threatening reaction. Peanut allergy symptoms can range from mild to severe. If you have a mild reaction, you may experience abdominal pain, a runny nose, itchy eyes, hives, or tingling in your lips or tongue. Your symptoms may begin within minutes to several hours of eating peanuts or peanut products.

Peanut Allergy Pipeline Insight Report

The Peanut Allergy Pipeline Report includes an in-depth commercial and clinical assessment of the pipeline products from the pre-clinical development stage to the market stage. The report also contains a detailed description of the drug, including the drug’s mechanism of action, clinical trials, NDA approvals (if any), and product development activities that encompass the technology, collaborations, mergers, acquisition, financing, naming and other product developments. related details.

Peanut allergy emerging drugs

  • Viaskin Peanut: DBV Technologies
  • Dupilumab: Regeneron Pharmaceuticals/Sanofi
  • CNP-201: Pharmaceutical Cour

Dive deep into rich insights for Peanut Allergy drug in the pipeline, visit @Peanut Allergy Treatment Landscape

Peanut Allergy Pipeline Therapeutics Analysis

There are approx. 15+ major companies developing the peanut allergy therapies. The companies that have their peanut allergy drug candidates in the most advanced stage, i.e. pre-registration, include DBV Technologies.

Scope of the Peanut Allergy Pipeline Report

  • Coverage – Worldwide
  • Peanut Allergy Companies- DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma SL, Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy, Prota Therapeutics, IgGenix and others.
  • Peanut Allergy Pipeline TherapiesASIT+, VLP Peanut, HAL-MPE1, INT301, INP20, CNP-201, VE416, Dupilumab, Acalabrutinib, CA002, Omalizumab and others
  • Peanut allergy key companies
  • Peanut allergy key products
  • Peanut Allergy – Unmet Needs

Index

  1. Introduction
  2. Peanut Allergy Summary
  3. Peanut allergy: overview
  4. Peanut Allergy Pipeline Therapeutics
  5. Therapeutic Assessment of Peanut Allergy
  6. Late Stage Products (Pre-Registration)
  7. Viaskin Peanut: DBV Technologies
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. Dupilumab: Regeneron Pharmaceuticals
  11. Drug profiles in the detailed report…..
  12. Early stage products (phase I/II)
  13. CNP-201: Pharmaceutical Cour
  14. Drug profiles in the detailed report…..
  15. Preclinical and Discovery Stage Products
  16. Peanut NE01 Vaccine: BlueWillow Biologics
  17. Drug profiles in the detailed report…..
  18. Inactive products
  19. Peanut allergy key companies
  20. Peanut allergy key products
  21. Peanut Allergy – Unmet Needs
  22. Peanut Allergy – Market Drivers and Barriers
  23. Peanut Allergy – Future Prospects and Conclusion
  24. Peanut Allergy Analysts Reviewed
  25. Peanut allergy key companies
  26. Appendix

Key questions

Current Treatment Scenario and Emerging Therapies:

  • How Many Companies Are Developing Peanut Allergy Drugs?
  • How Many Peanut Allergy Drugs Are Developed By Each Company?
  • How many emerging drugs are in mid- and late-stage development for the treatment of peanut allergy?
  • What are the major partnerships (industry – industry, industry – academia), mergers and acquisitions, licensing activities related to the Peanut Allergy therapeutics?
  • What are the recent trends, types of drugs and new technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies underway for peanut allergy and their status?
  • What are the main names assigned to the emerging drugs?

For more information on the Peanut Allergy pipeline therapies, contact Peanut Allergy Clinical Trials

Media contact
Company Name: DelveInsight Business Research LLP
Contact: Yash Bhardwaj
E-mail: send email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Peanut Allergy Pipeline | 15+ Companies & 15+ Medicines | DelveInsight

Leave a Reply

Your email address will not be published.

Scroll to top